Drug Profile
Metformin controlled-release/sitagliptin - Merck
Alternative Names: Januet XR; Janumet XR; MK-0431A XR; Sitagliptin/metformin HCl extended-release; Sitagliptin/metformin hydrochloride extended-releaseLatest Information Update: 15 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antihyperglycaemics; Biguanides; Insulin sensitisers; Pyrazines; Small molecules; Triazoles
- Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors; Glucose modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 21 Nov 2022 Galenicum Health completes a phase I trial in Type 2 diabetes mellitus (In volunteers) in Mexico (NCT06124573)
- 07 Nov 2022 Galenicum Health initiates enrolment in a phase I bioequivalence trial for Type 2 diabetes mellitus (In volunteers) in Mexico (NCT06124573)
- 22 Sep 2020 Phase-III development for Type 2 diabetes mellitus is ongoing in Georgia, Guatemala, Greece, Mauritius and Moldova (PO) (NCT01760447)